美纳里尼和Insilico Medicine通过潜在的5.5亿美元交易深化了人工智能合作伙伴关系-动脉网

Menarini, Insilico Medicine deepen AI partnership with potential $550M deal

MobiHealthNews 等信源发布 2025-01-13 19:40



可切换为仅中文







Photo: Zero Creatives GmbH/Getty Images

照片：Zero Creatives GmbH/Getty Images

Drug discovery startup

药物发现启动

Insilico Medicine

内科学

and Italian pharmaceutical company Menarini Group announced their second licensing agreement, targeting unmet needs in oncology with a novel AI-discovered preclinical asset.

意大利制药公司美纳里尼集团（Menarini Group）宣布了他们的第二份许可协议，针对肿瘤学中未满足的需求，开发了一种新型人工智能发现的临床前资产。

The agreement grants Stemline Therapeutics, a subsidiary of Menarini, global rights to develop and commercialize a selective small molecule inhibitor with broad anti-tumor activity.

该协议授予美纳里尼子公司Stemline Therapeutics开发和商业化具有广泛抗肿瘤活性的选择性小分子抑制剂的全球权利。

Developed using Insilico's Chemistry42 AI platform, the asset successfully completed preclinical trials.

该资产使用Insilico的Chemistry42 AI平台开发，成功完成了临床前试验。

Under the terms, Insilico will receive a $20 million upfront payment, with the deal's total potential value exceeding $550 million through development, regulatory and commercial milestones, plus tiered royalties.

根据这些条款，Insilico将获得2000万美元的预付款，通过开发、监管和商业里程碑以及分层版税，该交易的总潜在价值将超过5.5亿美元。

The partnership follows Menarini's 2024 acquisition of MEN2312, another AI-discovered asset targeting KAT6 inhibitors for breast cancer. MEN2312 rapidly progressed into clinical trials.

在美纳里尼于2024年收购MEN2312之后，美纳里尼与另一位AI发现的针对乳腺癌KAT6抑制剂的资产进行了合作。MEN2312迅速进入临床试验。

'We are thrilled to expand our collaboration with Insilico, a leader in generative AI,' Elcin Barker Ergun, CEO of the Menarini Group, said in a statement. 'This partnership allows us to address critical gaps in oncology treatment and reach more patients globally with innovative therapies.'

美纳里尼集团（Menarini Group）首席执行官埃尔辛·巴克·埃尔根（ElcinBarker Ergun）在一份声明中说，我们很高兴能扩大与创新人工智能领域领导者Insilico的合作这种伙伴关系使我们能够解决肿瘤学治疗中的关键差距，并通过创新疗法惠及全球更多患者。”

THE LARGER TREND

更大的趋势

This partnership highlights the potential of AI to revolutionize pharmaceutical innovation, enabling faster development of targeted therapies and the growing role of generative AI (genAI) in accelerating drug discovery and development.

这种伙伴关系突出了人工智能在彻底改变药物创新方面的潜力，使靶向治疗的发展更快，以及生成人工智能（genAI）在加速药物发现和开发方面的作用越来越大。

The technology is being leveraged for precision medicine, addressing critical unmet needs in cancer treatment and accelerating timelines from discovery to clinical application.

该技术正被用于精准医学，解决癌症治疗中尚未满足的关键需求，并加快从发现到临床应用的时间表。

Major technology companies, including

主要技术公司，包括

Google DeepMind and its AlphaProteo project

谷歌DeepMind及其AlphaProteo项目

are part of the evolution, as well as numerous startups across the globe, including

是进化的一部分，也是全球众多初创公司的一部分，包括

Israeli startup CytoReason

以色列初创企业CytoReason

, which recently received $80 million in a funding round.

，最近在一轮融资中获得了8000万美元。

In October,

十月，

AION Labs launched ProPhet

爱恩实验室推出ProPhet

, a startup using AI to accelerate drug discovery by identifying high-affinity small molecules for challenging protein targets, aiming to refine early-stage processes and reduce time and costs.

，这是一家使用AI通过识别具有挑战性的蛋白质靶标的高亲和力小分子来加速药物发现的初创公司，旨在改进早期过程并减少时间和成本。

IBM and German pharmaceutical company

IBM和德国制药公司

Boehringer Ingelheim

勃林格殷格翰

have also partnered to leverage IBM's

还合作利用IBM的

advanced large-scale neural network architectures

先进的大规模神经网络体系结构

to accelerate the discovery of therapeutic antibodies for treating cancer, autoimmune disorders, infectious diseases and other medical conditions.

加速发现治疗癌症、自身免疫性疾病、传染病和其他疾病的治疗性抗体。

In June 2024,